23andMe is exploring strategic alternatives, looking to raise capital
23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year. 23andMe said it will "need additional liquidity" to fund its operations, and it is looking to raise additional capital.
The health tech company formerly known as Allscripts, still reeling from failing to fix its financial reports, will have to ...
The Special Committee of the board of 23andMe Holding Co. announced that it has undertaken a process to explore strategic alternatives, including, among other alternatives, a poss ...
Genetic testing firm 23andMe (NASDAQ:ME) said it formed a special board committee to review strategic alternatives. The special committee will look at options including a sale, business combination, ...
Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...
After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...
Zacks.com on MSN11d
NGVT to Evaluate Strategic Alternatives for Industrial SpecialtiesIngevity Corporation NGVT recently announced plans to explore strategic alternatives for its Performance Chemicals Industrial ...
Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback